The Structure of Glycosaminoglycans and their Interactions with Proteins

被引:770
作者
Gandhi, Neha S. [1 ,2 ]
Mancera, Ricardo L. [1 ,2 ,3 ]
机构
[1] Curtin Univ Technol, Western Australian Biomed Res Inst, Perth, WA 6845, Australia
[2] Curtin Univ Technol, Sch Biomed Sci, Perth, WA 6845, Australia
[3] Curtin Univ Technol, Sch Pharm, Perth, WA 6845, Australia
关键词
carbohydrates; chondroitin sulphate; dermatan sulphate; glycosaminoglycans; heparan sulphate; heparin; hyaluronic acid; keratan sulphate; proteoglycans;
D O I
10.1111/j.1747-0285.2008.00741.x
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Glycosaminoglycans (GAGs) are important complex carbohydrates that participate in many biological processes through the regulation of their various protein partners. Biochemical, structural biology and molecular modelling approaches have assisted in understanding the molecular basis of such interactions, creating an opportunity to capitalize on the large structural diversity of GAGs in the discovery of new drugs. The complexity of GAG-protein interactions is in part due to the conformational flexibility and underlying sulphation patterns of GAGs, the role of metal ions and the effect of pH on the affinity of binding. Current understanding of the structure of GAGs and their interactions with proteins is here reviewed: the basic structures and functions of GAGs and their proteoglycans, their clinical significance, the three-dimensional features of GAGs, their interactions with proteins and the molecular modelling of heparin binding sites and GAG-protein interactions. This review focuses on some key aspects of GAG structure-function relationships using classical examples that illustrate the specificity of GAG-protein interactions, such as growth factors, anti-thrombin, cytokines and cell adhesion molecules. New approaches to the development of GAG mimetics as possible new glycotherapeutics are also briefly covered.
引用
收藏
页码:455 / 482
页数:28
相关论文
共 235 条
[1]   Pharmacological strategies for inhibition of thrombin activity [J].
Alban, S. .
CURRENT PHARMACEUTICAL DESIGN, 2008, 14 (12) :1152-1175
[2]   CONFORMATIONAL-ANALYSIS .130. MM2 - HYDROCARBON FORCE-FIELD UTILIZING V1 AND V2 TORSIONAL TERMS [J].
ALLINGER, NL .
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 1977, 99 (25) :8127-8134
[3]   MOLECULAR MECHANICS - THE MM3 FORCE-FIELD FOR HYDROCARBONS .1. [J].
ALLINGER, NL ;
YUH, YH ;
LII, JH .
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 1989, 111 (23) :8551-8566
[4]  
[Anonymous], 1986, EUR J BIOCHEM, V159, P1
[5]  
Åqvist J, 2001, COMB CHEM HIGH T SCR, V4, P613
[6]   The role of Arg46 and Arg47 of antithrombin in heparin binding [J].
Arocas, V ;
Bock, SC ;
Olson, ST ;
Björk, I .
BIOCHEMISTRY, 1999, 38 (31) :10196-10204
[7]   Lysine 114 of antithrombin is of crucial importance for the affinity and kinetics of heparin pentasaccharide binding [J].
Arocas, V ;
Bock, SC ;
Raja, S ;
Olson, ST ;
Björk, I .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (47) :43809-43817
[8]   Binding of selenoprotein P to heparin: Characterization with surface plasmon resonance [J].
Arteel, GE ;
Franken, S ;
Kappler, J ;
Sies, H .
BIOLOGICAL CHEMISTRY, 2000, 381 (03) :265-268
[9]   CD44 IS THE PRINCIPAL CELL-SURFACE RECEPTOR FOR HYALURONATE [J].
ARUFFO, A ;
STAMENKOVIC, I ;
MELNICK, M ;
UNDERHILL, CB ;
SEED, B .
CELL, 1990, 61 (07) :1303-1313
[10]   INTERACTION OF HEPARIN WITH SYNTHETIC ANTITHROMBIN-III PEPTIDE ANALOGS [J].
BAE, JH ;
DESAI, UR ;
PERVIN, A ;
CALDWELL, EEO ;
WEILER, JM ;
LINHARDT, RJ .
BIOCHEMICAL JOURNAL, 1994, 301 :121-129